Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577534 | 0.92 | ALDH1A1 (0.54) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL5577508 | 0.92 | DRD2 (0.58) | CCR5ABCB1ACHEBCHELMNA | |
| SCHEMBL5577417 | 0.91 | NR1H4 (0.58) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL5577689 | 0.89 | CCR5 (0.61) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL5577714 | 0.89 | NR1H4 (0.53) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL5577836 | 0.89 | TSHR (0.59) | CCR5ALDH1A1POLBGAAACHE | |
| SCHEMBL5577594 | 0.89 | ALDH1A1 (0.54) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL5577516 | 0.88 | ALDH1A1 (0.66) | CCR5ABCB1ALDH1A1POLBGAA | |
| SCHEMBL14586598 | 0.88 | LMNA (0.55) | CCR5ABCB1ALDH1A1POLBGAA | |
| Hydrochloric Acid SCHEMBL5577422 | 0.87 | LMNA (0.54) | CCR5ABCB1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CCR5 183/4885ABCB1 325/4885ALDH1A1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.